THE COMPLICATIONS OF CHRONIC KIDNEY DISEASE, SECOND EDITION Final Examination Questions Select the best answer for each question and then proceed to EliteLearning.com/Book to complete your final examination.
126. The National Kidney Foundation recommends using _______ to estimate GFR. a. CKD-EPI creatinine equation.
131. If an increase in serum creatinine of more than _______ oc- curs within four weeks of starting or increasing the dose of an ACE inhibitor or ARB, the medication should be stopped.
b. Cockroft–Gault Equation. c. 24-hour urine collection. d. Jelliffe equation.
a. 10%. b. 20%. c. 30%. d. 40%.
127. The Kidney Disease: Improving Global Outcomes (KDIGO) Work Group defines chronic kidney disease as abnormali - ties of kidney structure or function, present for greater than _______, with implications for health. a. Three days. b. Three months. c. Ttwo weeks. d. 30 days. 128. Which of the following accurately describes stage 4 CKD? a. Markers of kidney damage found, but GFR is normal or increased (>90 mL/min/1.73 m 2 ). b. Mildly reduced GFR (60–89 mL/min/1.73 m 2 ). c. Severely reduced GFR (15–29 mL/min/1.73 m 2 ). d. Kidney failure (GFR <15 mL/min/1.73 m 2 or dialysis). 129. The KDIGO Work Group recommends restricting dietary sodium to _______ per day in all adult CKD patients unless contraindicated. a. Less than 4 grams. b. Less than 2 grams. c. Greater than 2 grams. d. Less than 1 gram. 130. The KDOQI Work Group suggests a target systolic blood pressure of _______ in CKD patients.
132. _______ is a rare earth element that has effectiveness in re- ducing phosphate levels in chronic kidney disease patients. a. Lanthanum. b. Calcium carbonate. c. Doxercalciferol. d. Cinacalcet. 133. _______ is an iron-based chewable phosphate binder sold under the name Velphoro. a. Sevelamer. b. Sucroferric oxyhydroxide. c. Lanthanum. d. Calcium acetate. 134. _______ is the activated form of vitamin D. a. Calcitriol. b. Doxercalciferol. c. Paricalcitol. d. Calcium acetate. 135. Unlike vitamin D analogs, calcimimetics can be administered in patients with:
a. Hyperphosphatemia. b. Hypoparathyroidism. c. Hypertension. d. Hyperlipidemia.
a. Less than 120 mmHg. b. Less than 130 mmHg. c. Less than 135 mmHg. d. Less than 140 mmHg
Course Code: RPTX02CK
Page 157
Book Code: RPTX3024
EliteLearning.com/Pharmacy
Powered by FlippingBook